EGI
FATE icon

EAM Global Investors’s Fate Therapeutics FATE Stock Holding History

EAM Global Investors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-49,796
Closed -$773K – 123
2019
Q3 		$773K Sell
49,796
-41,536
-45% -$796K 0.38% 109
2019
Q2 		$1.85M Hold
91,332
– – 0.79% 41
2019
Q1 		$1.6M Sell
91,332
-11,793
-11% -$186K 0.71% 62
2018
Q4 		$1.32M Hold
103,125
– – 0.72% 70
2018
Q3 		$1.68M Buy
103,125
+25,236
+32% +$298K 0.68% 48
2018
Q2 		$883K Hold
77,889
– – 0.43% 136
2018
Q1 		$760K Buy
+77,889
New +$746K 0.39% 127

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

EAM Global Investors's FATE Position: Q4 2019 in Review

EAM Global Investors sold out of Fate Therapeutics (FATE) in Q4 2019, closing a stake of 49,796 shares — an estimated $773K sold.

EAM Global Investors first reported a position in FATE in Q1 2018 and held it in 7 quarters. The position peaked at $1.85M in Q2 2019. 147 funds tracked by Wall St. Rank hold FATE as of Q4 2019.

  • EAM Global Investors reported no remaining Fate Therapeutics position as of Q4 2019 after selling out during the quarter.
  • EAM Global Investors sold 49,796 Fate Therapeutics shares in Q4 2019, an estimated $773K.
  • EAM Global Investors first reported a position in Fate Therapeutics in Q1 2018 and held it in 7 quarters.
  • EAM Global Investors's Fate Therapeutics position peaked at $1.85M in Q2 2019.
  • 147 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2019.

Based on EAM Global Investors's 13F filing for Q4 2019, filed 10 Feb 2020.